Jun 14, 2022 / 04:20PM GMT
Paul Choi - Goldman Sachs Group, Inc., Research Division - Equity Analyst
Okay. Good morning. We'll continue with the next session. I'm Paul Choi, and I cover the smidcap biotechnology sector here at the firm. And it's my pleasure to welcome NGM. Joining us from management to my left, immediate left, is David Woodhouse, CEO; and to my far left, Siobhan Mangini, CFO. What we'll do is a little bit of Q&A. If any audience members along the way have any questions, please raise your hand and we can get a microphone to you. Otherwise, we'll just go ahead and start with David and Siobhan.
Questions and Answers:
Paul Choi - Goldman Sachs Group, Inc., Research Division - Equity AnalystSo maybe perhaps most topical is people's interest in geographic atrophy, just given the news and events over the past few quarters here. And so can you maybe frame for us how you think about the market opportunity today, how do you think about the competitive landscape and how maybe some of the key things that investors focus on like the complement pathway and its various
Trustpilot
